| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17426 R73197 |
Madley-Dowd_SE (Carbamazepine) (Controls exposed to LTG), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No Partial overlapping |
2.47 [1.76;3.47] C excluded (control group) |
98/1,842 53/2,383 | 151 | 1,842 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17427 R73198 |
Madley-Dowd_SE (Carbamazepine) (Controls unexposed, sick), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Partial overlapping | 1.16 [0.92;1.45] | 98/1,842 425/10,769 | 523 | 1,842 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17257 R72269 |
Madley-Dowd_UK (Carbamazepine) (Controls exposed to LTG), 2024 | Autism - ICD10 codes - Median CBZ 9.17 (5.31-12.54) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
1.75 [0.88;3.46] C excluded (control group) |
17/460 17/791 | 34 | 460 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17107 R72270 |
Madley-Dowd_UK (Carbamazepine) (Controls unexposed, sick), 2024 | Autism - ICD10 codes - Median CBZ 9.17 (5.31-12.54) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 1.68 [0.91;3.09] | 17/460 78/4,075 | 95 | 460 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15868 R65362 |
Dreier (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023 | Autism spectrum disorder - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
1.31 [0.88;1.93] C excluded (control group) |
42/2,665 64/5,288 | 106 | 2,665 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15869 R65378 |
Dreier (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 | Autism spectrum disorder - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: Yes | 1.03 [0.70;1.51] | 42/2,665 323/22,203 | 365 | 2,665 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10075 R46619 |
Blotiere (Carbamazepine), 2020 | Diagnosis Pervasive developmental disorders (F84) (mean age of 3.7 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick | Adjustment: No | 0.80 [0.05;14.03] C | 0/176 7/2,108 | 7 | 176 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7510 R46620 |
Huber-Mollema (Carbamazepine), 2019 | Diagnosis of autism spectrum disorder | throughout pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.20 [0.21;6.85] C | 2/37 4/88 | 6 | 37 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9978 R46623 |
Bjørk (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
0.83 [0.29;2.38] C excluded (control group) |
6/41 13/76 | 19 | 41 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9979 R46624 |
Bjørk (Carbamazepine) (Controls unexposed, disease free), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, disease free excluded | Adjustment: No |
1.70 [0.72;4.05] C excluded (control group) |
6/41 6,907/75,497 | 6,913 | 41 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9980 R46625 |
Bjørk (Carbamazepine) (Controls unexposed, sick), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: No | 1.56 [0.60;4.03] C | 6/41 27/272 | 33 | 41 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6181 R46622 |
Wood (Carbamazepine), 2015 | Score >30 (CARS) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.78 [0.03;21.03] C | 1/34 0/9 | 1 | 34 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6661 R46616 |
Bromley (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 | Autistic Spectrum Disorders (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.19 [0.01;4.87] C excluded (control group) |
0/50 1/30 | 1 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6660 R46617 |
Bromley (Carbamazepine) (Controls unexposed, disease free), 2013 | Autistic Spectrum Disorders (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
0.47 [0.02;8.88] C excluded (control group) |
0/50 4/214 | 4 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5486 R46618 |
Bromley (Carbamazepine) (Controls unexposed, sick), 2013 | Autistic Spectrum Disorders (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.52 [0.01;26.73] C | 0/50 0/26 | 0 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 8 studies | 1.17 [0.98;1.41] | 1,030 | 5,305 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Carbamazepine) (Controls unexposed, sick; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine) (Epilepsy) (Controls unexposed, sick; 4: Carbamazepine; 5: Carbamazepine; 6: Carbamazepine) (Controls unexposed, sick; 7: Carbamazepine; 8: Carbamazepine) (Controls unexposed, sick;
Asymetry test p-value = 0.9674 (by Egger's regression)
slope=0.1586 (0.0837); intercept=0.0136 (0.3202); t=0.0426; p=0.9674
excluded 6661, 6660, 9978, 9979, 15868, 17426, 17257